MetaVia Inc. (MTVA)
| Market Cap | 19.88M +177.7% |
| Revenue (ttm) | n/a |
| Net Income | -13.13M |
| EPS | -4.79 |
| Shares Out | 5.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,338,052 |
| Open | 3.560 |
| Previous Close | 2.870 |
| Day's Range | 3.350 - 4.310 |
| 52-Week Range | 0.966 - 19.029 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 19.33 (+402.08%) |
| Earnings Date | May 14, 2026 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MTVA stock is "Buy." The 12-month stock price target is $19.33, which is an increase of 402.08% from the latest price.
News
3 Penny Stocks to Watch Now, 5/21/26
HCW Biologics ($HCWB), MetaVia ($MTVA), and Silexion Therapeutics ($SLXN) are the three penny stocks to watch on May 21, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to low-pri...
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the publication of ...
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-st...
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Pat...
MetaVia Earnings release: Q1 2026
MetaVia released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
MetaVia Quarterly report: Q1 2026
MetaVia has published its Q1 2026 quarterly earnings report on May 14, 2026.
MetaVia Slides: Investor presentation
MetaVia has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breakin...
MetaVia Proxy statement: Proxy filing
MetaVia filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
MetaVia Proxy statement: Proxy filing
MetaVia filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726
MetaVia (MTVA) announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and…
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: M...
MetaVia: Cash position adequate to fund operations into 4Q26
Cash and cash equivalents were $10.3M as of December 31, 2025, compared with $16M as of December 31, 2024. With these funds and proceeds from the January 2026 public offering,…
MetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’
“We made significant progress advancing our cardiometabolic portfolio during the year, punctuated by the positive data, released in January of this year, from the Phase 1 extended 8-week, non-titrated...
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned Phase 1 Part 3 16-Week Titration Study to Ev...
MetaVia Annual report: Q4 2025
MetaVia has published its Q4 2025 annual report on March 26, 2026.
MetaVia Earnings release: Q4 2025
MetaVia released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
MetaVia Slides: Investor presentation
MetaVia has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
MetaVia announces IRB at Clinical Pharmacology of Miami approved Phase 1 study
MetaVia (MTVA) announced that the Institutional Review Board, IRB, at Clinical Pharmacology of Miami has approved the Company’s Phase 1 Part 3 clinical trial of its lead asset, DA-1726, a…
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq:...
MetaVia Transcript: Life Sciences Virtual Investor Forum
DA-1726, a dual GLP-1/glucagon agonist, shows rapid and significant weight and waist reduction with promising metabolic and liver benefits. Upcoming trials aim for higher efficacy and improved tolerability, with key data expected before year-end.
MetaVia expands global patent protection for vanoglipel into 2035
MetaVia (MTVA) announced a comprehensive global intellectual property portfolio supporting vanoglipel, its novel, orally available G-protein-coupled receptor 119 agonist. This currently includes 48 gr...
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
Patent Portfolio Includes 48 Granted and Pending Patents in the U.S., Europe, Japan, China and other Countries, Providing Protection Into 2035, Unless Extended Further CAMBRIDGE, Mass., March 12, 2026...
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Ki...
MetaVia Transcript: Emerging Growth Virtual Conference
Significant progress was reported for two cardiometabolic assets, with DA-1726 showing strong early efficacy in obesity and vanoglipel meeting endpoints in MASH. Upcoming data releases and ongoing phase I titration studies are expected to drive value, supported by a solid cash position and active partnership discussions.